Could a year of targeted therapy cure breast cancer that has spread just a little?
NCT ID NCT05982678
First seen Jan 08, 2026 · Last updated May 10, 2026 · Updated 18 times
Summary
This study tests a drug called trastuzumab-deruxtecan (T-DXd) in people with HER2-positive breast cancer that has spread to 1-5 distant spots (oligo-metastatic). The goal is to shrink or eliminate all cancer with a year of treatment, including local therapies like radiation or surgery, and potentially achieve a cure. About 72 participants will receive T-DXd every 3 weeks for 16 cycles.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2-POSITIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-••••
Locations
-
Antoni van Leeuwenhoek
RECRUITINGAmsterdam, Netherlands
Contact
Contact
Contact
Conditions
Explore the condition pages connected to this study.